

Jens D Lundgren

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1869606/publications.pdf>

Version: 2024-02-01

471
papers

44,593
citations

4146

87
h-index

2385

198
g-index

478
all docs

478
docs citations

478
times ranked

37795
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trial. <i>European Respiratory Journal</i> , 2022, 59, 2100752. | 6.7 | 31 |
| 2 | Bacterial and fungal bloodstream infections in solid organ transplant recipients: results from a Danish cohort with nationwide follow-up. <i>Clinical Microbiology and Infection</i> , 2022, 28, 391-397. | 6.0 | 9 |
| 3 | Improving healthcare for patients with HIV, tuberculosis and hepatitis C in eastern Europe: a review of current challenges and important next steps. <i>HIV Medicine</i> , 2022, 23, 48-59. | 2.2 | 7 |
| 4 | The hepatitis C cascade of care in HIV/hepatitis C virus coinfecting individuals in Europe: regional and intra-regional differences. <i>Aids</i> , 2022, 36, 423-435. | 2.2 | 8 |
| 5 | <i>Clostridioides difficile</i> infection in solid organ and hematopoietic stem cell transplant recipients: A prospective multinational study. <i>Transplant Infectious Disease</i> , 2022, 24, e13770. | 1.7 | 3 |
| 6 | Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?. <i>European Journal of Haematology</i> , 2022, 108, 369-378. | 2.2 | 5 |
| 7 | Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial. <i>Lancet</i> , 2022, 399, 530-540. | 13.7 | 48 |
| 8 | Integrase strand transfer inhibitor use and cancer incidence in a large cohort setting. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac029. | 0.9 | 3 |
| 9 | Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels. <i>Annals of Internal Medicine</i> , 2022, 175, 234-243. | 3.9 | 56 |
| 10 | RAGE has potential pathogenetic and prognostic value in nonintubated hospitalized patients with COVID-19. <i>JCI Insight</i> , 2022, 7, . | 5.0 | 17 |
| 11 | Characteristics associated with serological COVID-19 vaccine response and durability in an older population with significant comorbidity: the Danish Nationwide ENFORCE Study. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1126-1133. | 6.0 | 30 |
| 12 | Cytomegalovirus viremia and risk of disease progression and death in HIV-positive patients starting antiretroviral therapy. <i>Aids</i> , 2022, Publish Ahead of Print, . | 2.2 | 7 |
| 13 | Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess Recovery. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 730-739. | 5.6 | 10 |
| 14 | Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium. <i>Lancet HIV</i> , 2022, 9, e474-e485. | 4.7 | 48 |
| 15 | Pulmonary Arterial Enlargement in Well-Treated Persons With Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2021, 223, 94-100. | 4.0 | 1 |
| 16 | The Impact of Immunosuppression on Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: The D:A:D Study. <i>Journal of Infectious Diseases</i> , 2021, 223, 632-637. | 4.0 | 6 |
| 17 | A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 905-914. | 27.0 | 357 |
| 18 | Identification of two different coagulation phenotypes in people living with HIV with undetectable viral replication. <i>Scientific Reports</i> , 2021, 11, 4383. | 3.3 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Causes and outcomes of hospitalizations among people living with HIV in Georgia's referral institution, 2012-2017. <i>International Journal of STD and AIDS</i> , 2021, 32, 662-670. | 1.1 | 0 |
| 20 | Genome-wide association study of high-sensitivity C-reactive protein, D-dimer, and interleukin-6 levels in multiethnic HIV+ cohorts. <i>Aids</i> , 2021, 35, 193-204. | 2.2 | 6 |
| 21 | Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 248-257. | 2.1 | 3 |
| 22 | Cost-effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States. <i>Journal of the International AIDS Society</i> , 2021, 24, e25690. | 3.0 | 5 |
| 23 | Effect of Changes in Body Mass Index on the Risk of Cardiovascular Disease and Diabetes Mellitus in HIV-Positive Individuals: Results From the D:A:D Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 579-586. | 2.1 | 16 |
| 24 | ABO blood types and sepsis mortality. <i>Annals of Intensive Care</i> , 2021, 11, 61. | 4.6 | 5 |
| 25 | Response to Aviv et al. <i>Journal of Infectious Diseases</i> , 2021, 224, 559-561. | 4.0 | 5 |
| 26 | Human Immunotypes Impose Selection on Viral Genotypes Through Viral Epitope Specificity. <i>Journal of Infectious Diseases</i> , 2021, 224, 2053-2063. | 4.0 | 6 |
| 27 | Phylogenetic analysis of HIV-1 shows frequent cross-country transmission and local population expansions. <i>Virus Evolution</i> , 2021, 7, veab055. | 4.9 | 5 |
| 28 | Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 2031-2036. | 5.8 | 68 |
| 29 | Hydroxychloroquine as a primary prophylactic agent against SARS-CoV-2 infection: A cohort study. <i>International Journal of Infectious Diseases</i> , 2021, 108, 370-376. | 3.3 | 5 |
| 30 | Development and Dynamics of Cytomegalovirus UL97 Ganciclovir Resistance Mutations in Transplant Recipients Detected by Next Generation Sequencing. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab462. | 0.9 | 4 |
| 31 | Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment-Experienced People Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021, 73, e2323-e2333. | 5.8 | 16 |
| 32 | The association of human leukocyte antigen alleles with clinical disease progression in HIV-positive cohorts with varied treatment strategies. <i>Aids</i> , 2021, 35, 783-789. | 2.2 | 2 |
| 33 | Inflammation and Platelet Activation After COVID-19 Vaccines - Possible Mechanisms Behind Vaccine-Induced Immune Thrombocytopenia and Thrombosis. <i>Frontiers in Immunology</i> , 2021, 12, 779453. | 4.8 | 59 |
| 34 | 29. Sustained Recovery in Patients Admitted to Hospital With COVID-19. <i>Open Forum Infectious Diseases</i> , 2021, 8, S20-S21. | 0.9 | 0 |
| 35 | 23. Development and Validation of a Risk Score for Post-transplant Lymphoproliferative Disorders among Solid Organ Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2021, 8, S15-S16. | 0.9 | 0 |
| 36 | Development and validation of a cycle-specific risk score for febrile neutropenia during chemotherapy cycles 2-6 in patients with solid cancers: The CSR FENCE score. <i>International Journal of Cancer</i> , 2020, 146, 321-328. | 5.1 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Poor Concordance Between Liver Stiffness and Noninvasive Fibrosis Scores in HIV Infection Without Viral Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 3049-3050. | 4.4 | 2 |
| 38 | Impact of Human Immunodeficiency Virus-Related Gut Microbiota Alterations on Metabolic Comorbid Conditions. <i>Clinical Infectious Diseases</i> , 2020, 71, e359-e367. | 5.8 | 36 |
| 39 | Fraction of Exhaled Nitric Oxide Levels Are Elevated in People Living With Human Immunodeficiency Virus Compared to Uninfected Controls, Suggesting Increased Eosinophilic Airway Inflammation. <i>Clinical Infectious Diseases</i> , 2020, 71, 3214-3221. | 5.8 | 9 |
| 40 | Epidemiology of hepatitis E virus infection in a cohort of 4023 immunocompromised patients. <i>International Journal of Infectious Diseases</i> , 2020, 91, 188-195. | 3.3 | 13 |
| 41 | Evaluation of an electronic, patient-focused management system aimed at preventing cytomegalovirus disease following solid organ transplantation. <i>Transplant Infectious Disease</i> , 2020, 22, e13252. | 1.7 | 23 |
| 42 | Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy. <i>Journal of Infectious Diseases</i> , 2020, 222, 1103-1107. | 4.0 | 123 |
| 43 | Case Report: Hyper IgM Syndrome Identified by Whole Genome Sequencing in a Young Syrian Man Presenting With Atypical, Severe and Recurrent Mucosal Leishmaniasis. <i>Frontiers in Immunology</i> , 2020, 11, 567856. | 4.8 | 1 |
| 44 | Increased Prevalence of Liver Fibrosis in People Living With Human Immunodeficiency Virus Without Viral Hepatitis Compared to Population Controls. <i>Journal of Infectious Diseases</i> , 2020, 224, 443-452. | 4.0 | 6 |
| 45 | Prevalence and Risk Factors of Moderate-to-Severe Hepatic Steatosis in Human Immunodeficiency Virus Infection: The Copenhagen Co-morbidity Liver Study. <i>Journal of Infectious Diseases</i> , 2020, 222, 1353-1362. | 4.0 | 17 |
| 46 | Tuberculosis among Patients Undergoing Solid Organ Transplantation or Dialysis in a Low-Endemic Country, 2004-2017. <i>Tuberculosis Research and Treatment</i> , 2020, 2020, 1-7. | 0.6 | 4 |
| 47 | Mortality and admission to intensive care units after febrile neutropenia in patients with cancer. <i>Cancer Medicine</i> , 2020, 9, 3033-3042. | 2.8 | 20 |
| 48 | Preoperative TruCulture® whole blood cytokine response predicts postoperative inflammation in pancreaticoduodenectomy patients: A pilot cohort study. <i>Scandinavian Journal of Immunology</i> , 2020, 92, e12930. | 2.7 | 13 |
| 49 | Measles, Mumps, Rubella, and Varicella Zoster Virus Serology and Infections in Solid Organ Transplant Recipients During the First Year Posttransplantation. <i>Clinical Infectious Diseases</i> , 2020, 73, e3733-e3739. | 5.8 | 7 |
| 50 | Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 240-250. | 2.1 | 24 |
| 51 | Machine learning can identify newly diagnosed patients with CLL at high risk of infection. <i>Nature Communications</i> , 2020, 11, 363. | 12.8 | 75 |
| 52 | Interstitial Lung Abnormalities in People With HIV Infection and Uninfected Controls. <i>Journal of Infectious Diseases</i> , 2020, 221, 1973-1977. | 4.0 | 8 |
| 53 | Pericardial Adipose Tissue Volume Is Independently Associated With Human Immunodeficiency Virus Status and Prior Use of Stavudine, Didanosine, or Indinavir. <i>Journal of Infectious Diseases</i> , 2020, 222, 54-61. | 4.0 | 9 |
| 54 | Remdesivir for the Treatment of Covid-19 – Final Report. <i>New England Journal of Medicine</i> , 2020, 383, 1813-1826. | 27.0 | 5,834 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium. PLoS ONE, 2020, 15, e0243625. | 2.5 | 8 |
| 56 | Influence of Hepatitis C Coinfection and Treatment on Risk of Diabetes Mellitus in HIV-Positive Persons. Open Forum Infectious Diseases, 2020, 7, ofaa470. | 0.9 | 1 |
| 57 | 252. Increased incidence rates of positive blood cultures shortly after chemotherapy treatment initiation among individuals treated for solid malignant tumours. Open Forum Infectious Diseases, 2020, 7, S125-S126. | 0.9 | 0 |
| 58 | 1075. Absolute Lymphocyte Count as a Predictor of Cytomegalovirus (CMV) Infection and Recurrence in Hematopoietic Stem Cell Transplant (HSCT) Recipients. Open Forum Infectious Diseases, 2020, 7, S565-S565. | 0.9 | 1 |
| 59 | 1079. The Risk of Cytomegalovirus (CMV) Infection and Recurrence Among Solid Organ Transplant Recipients. Open Forum Infectious Diseases, 2020, 7, S567-S568. | 0.9 | 1 |
| 60 | Cessation of Cigarette Smoking and the Impact on Cancer Incidence in Human Immunodeficiency Virus-infected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. Clinical Infectious Diseases, 2019, 68, 650-657. | 5.8 | 21 |
| 61 | The Effect of Interrupted/Deferred Antiretroviral Therapy on Disease Risk: A SMART and START Combined Analysis. Journal of Infectious Diseases, 2019, 219, 254-263. | 4.0 | 13 |
| 62 | Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials. Clinical Infectious Diseases, 2019, 68, 1420-1426. | 5.8 | 136 |
| 63 | Long-lasting alterations in adipose tissue density and adiponectin production in people living with HIV after thymidine analogues exposure. BMC Infectious Diseases, 2019, 19, 708. | 2.9 | 9 |
| 64 | Increased Risk of Anemia, Neutropenia, and Thrombocytopenia in People With Human Immunodeficiency Virus and Well-Controlled Viral Replication. Journal of Infectious Diseases, 2019, 220, 1834-1842. | 4.0 | 12 |
| 65 | Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. Journal of Infectious Diseases, 2019, 220, 1629-1634. | 4.0 | 8 |
| 66 | Immune function as predictor of infectious complications and clinical outcome in patients undergoing solid organ transplantation (the ImmuneMo:SOT study): a prospective non-interventional observational trial. BMC Infectious Diseases, 2019, 19, 573. | 2.9 | 10 |
| 67 | Incomplete ART adherence is associated with higher inflammation in individuals who achieved virologic suppression in the START study. Journal of the International AIDS Society, 2019, 22, e25297. | 3.0 | 26 |
| 68 | Risk Factors for Failure of Primary (Val)ganciclovir Prophylaxis Against Cytomegalovirus Infection and Disease in Solid Organ Transplant Recipients. Open Forum Infectious Diseases, 2019, 6, ofz215. | 0.9 | 21 |
| 69 | 2569. The Gut Microbiome and Acute Graft vs. Host Disease Risk in Hematopoietic Stem Cell Transplantation Recipients. Open Forum Infectious Diseases, 2019, 6, S892-S893. | 0.9 | 0 |
| 70 | Abdominal Adipose Tissue Is Associated With Alterations in Tryptophan-Kynurenine Metabolism and Markers of Systemic Inflammation in People With Human Immunodeficiency Virus. Journal of Infectious Diseases, 2019, 221, 419-427. | 4.0 | 12 |
| 71 | Predictors of Ischemic and Hemorrhagic Strokes Among People Living With HIV: The D:A:D International Prospective Multicohort Study. EClinicalMedicine, 2019, 13, 91-100. | 7.1 | 15 |
| 72 | Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapy-naïve Participants From the Strategic Timing of AntiRetroviral Treatment Trial. Journal of Infectious Diseases, 2019, 220, 1325-1334. | 4.0 | 18 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 73 | Effect Estimates in Randomized Trials and Observational Studies: Comparing Apples With Apples. <i>American Journal of Epidemiology</i> , 2019, 188, 1569-1577. | 3.4 | 75 |
| 74 | Efficacy of seven and fourteen days of antibiotic treatment in uncomplicated <i>Staphylococcus aureus</i> bacteremia (SAB7): study protocol for a randomized controlled trial. <i>Trials</i> , 2019, 20, 250. | 1.6 | 18 |
| 75 | Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. <i>Lancet, The</i> , 2019, 393, 2428-2438. | 13.7 | 627 |
| 76 | Biomarker-assisted identification of sepsis-related acute liver impairment: a frequent and deadly condition in critically ill patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1422-1431. | 2.3 | 11 |
| 77 | Incidence Rates and Risk Factors of <i>Clostridioides difficile</i> Infection in Solid Organ and Hematopoietic Stem Cell Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz086. | 0.9 | 17 |
| 78 | 2613. The Epidemiology of Respiratory Syncytial Virus (RSV) in People with Immune Dysfunction Seen at a Tertiary Hospital Between 2010 and 2017. <i>Open Forum Infectious Diseases</i> , 2019, 6, S908-S909. | 0.9 | 0 |
| 79 | 2670. <i>Clostridioides difficile</i> Infection (CDI) in Solid-Organ (SOT) and Hematopoietic Stem Cell Transplant (HCT) Recipients: A Prospective Multinational Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, S936-S936. | 0.9 | 0 |
| 80 | Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression Among Participants Initiating Antiretroviral Treatment With CD4+ Counts \geq 500 Cells/mm ³ : Findings From the Strategic Timing of Antiretroviral Therapy (START) Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 10-17. | 2.1 | 13 |
| 81 | Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe. <i>Aids</i> , 2019, 33, 2013-2024. | 2.2 | 13 |
| 82 | Serious clinical events in HIV-positive persons with chronic kidney disease. <i>Aids</i> , 2019, 33, 2173-2188. | 2.2 | 7 |
| 83 | Prevalence and risk factors of prolonged QT interval and electrocardiographic abnormalities in persons living with HIV. <i>Aids</i> , 2019, 33, 2205-2210. | 2.2 | 14 |
| 84 | Prior exposure to thymidine analogs and didanosine is associated with long-lasting alterations in adipose tissue distribution and cardiovascular risk factors. <i>Aids</i> , 2019, 33, 675-683. | 2.2 | 34 |
| 85 | Risk factors for antiretroviral therapy (ART) discontinuation in a large multinational trial of early ART initiators. <i>Aids</i> , 2019, 33, 1385-1390. | 2.2 | 3 |
| 86 | A Large-Cohort, Longitudinal Study Determines Precancer Disease Routes across Different Cancer Types. <i>Cancer Research</i> , 2019, 79, 864-872. | 0.9 | 17 |
| 87 | Epidemiology of bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal nation-wide cohort study. <i>Leukemia</i> , 2019, 33, 662-670. | 7.2 | 26 |
| 88 | Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study. <i>Lancet HIV, the</i> , 2019, 6, e116-e127. | 4.7 | 84 |
| 89 | The Association between Detected drug Resistance Mutations and CD4 ⁺ T-Cell Decline in HIV-Positive Individuals Maintained on a Failing Treatment Regimen. <i>Antiviral Therapy</i> , 2018, 23, 105-116. | 1.0 | 3 |
| 90 | Serious Non-AIDS Conditions in HIV: Benefit of Early ART. <i>Current HIV/AIDS Reports</i> , 2018, 15, 162-171. | 3.1 | 16 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 91 | Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study. <i>Journal of the International AIDS Society</i> , 2018, 21, e25083. | 3.0 | 10 |
| 92 | Higher Risk of Abdominal Obesity, Elevated Low-Density Lipoprotein Cholesterol, and Hypertriglyceridemia, but not of Hypertension, in People Living With Human Immunodeficiency Virus (HIV): Results From the Copenhagen Comorbidity in HIV Infection Study. <i>Clinical Infectious Diseases</i> , 2018, 67, 579-586. | 5.8 | 73 |
| 93 | Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial. <i>Lancet HIV</i> , 2018, 5, e172-e180. | 4.7 | 28 |
| 94 | Airflow limitation in people living with HIV and matched uninfected controls. <i>Thorax</i> , 2018, 73, 431-438. | 5.6 | 57 |
| 95 | No neurocognitive advantage for immediate antiretroviral treatment in adults with greater than 500 CD4+ T-cell counts. <i>Aids</i> , 2018, 32, 985-997. | 2.2 | 15 |
| 96 | Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study. <i>Lancet HIV</i> , 2018, 5, e146-e154. | 4.7 | 61 |
| 97 | Differences in Virological and Immunological Risk Factors for Non-Hodgkin and Hodgkin Lymphoma. <i>Journal of the National Cancer Institute</i> , 2018, 110, 598-607. | 6.3 | 12 |
| 98 | Induced hypothermia in patients with septic shock and respiratory failure (CASS): a randomised, controlled, open-label trial. <i>Lancet Respiratory Medicine</i> , 2018, 6, 183-192. | 10.7 | 51 |
| 99 | Uptake of Tenofovir-Based Antiretroviral Therapy among HIV-HBV-Coinfected Patients in the EuroSIDA Study. <i>Antiviral Therapy</i> , 2018, 23, 405-413. | 1.0 | 5 |
| 100 | Prevention of HIV transmission by antiretroviral therapy. <i>Lancet HIV</i> , 2018, 5, e108-e109. | 4.7 | 7 |
| 101 | Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. <i>Lancet HIV</i> , 2018, 5, e291-e300. | 4.7 | 155 |
| 102 | Serum Albumin as a Prognostic Marker for Serious Non-AIDS Endpoints in the Strategic Timing of Antiretroviral Treatment (START) Study. <i>Journal of Infectious Diseases</i> , 2018, 217, 405-412. | 4.0 | 17 |
| 103 | Abacavir use and risk of recurrent myocardial infarction. <i>Aids</i> , 2018, 32, 79-88. | 2.2 | 15 |
| 104 | Cytomegalovirus Viral Load in Bronchoalveolar Lavage to Diagnose Lung Transplant Associated CMV Pneumonia. <i>Transplantation</i> , 2018, 102, 326-332. | 1.0 | 40 |
| 105 | Contemporary protease inhibitors and cardiovascular risk. <i>Current Opinion in Infectious Diseases</i> , 2018, 31, 8-13. | 3.1 | 28 |
| 106 | Quantification of sexual HIV transmission risk in Africa. <i>International Journal of Infectious Diseases</i> , 2018, 66, 135-136. | 3.3 | 0 |
| 107 | Where is the greatest impact of uncontrolled HIV infection on AIDS and non-AIDS events in HIV?. <i>Aids</i> , 2018, 32, 205-215. | 2.2 | 5 |
| 108 | Brief Report: Prevalence of Peripheral Artery Disease Is Higher in Persons Living With HIV Compared With Uninfected Controls. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 381-385. | 2.1 | 21 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Development and Validation of a Risk Score for Febrile Neutropenia After Chemotherapy in Patients With Cancer: The FENCE Score. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky053. | 2.9 | 27 |
| 110 | Impact of CMV PCR Blips in Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation. <i>Transplantation Direct</i> , 2018, 4, e355. | 1.6 | 12 |
| 111 | Association of Suboptimal Antiretroviral Therapy Adherence With Inflammation in Virologically Suppressed Individuals Enrolled in the SMART Study. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofx275. | 0.9 | 18 |
| 112 | Classification of death causes after transplantation (CLASS). <i>Medicine (United States)</i> , 2018, 97, e11564. | 1.0 | 14 |
| 113 | Variation in antiretroviral treatment coverage and virological suppression among three HIV key populations. <i>Aids</i> , 2018, 32, 2807-2819. | 2.2 | 13 |
| 114 | Febrile Neutropenia and Long-term Risk of Infection Among Patients Treated With Chemotherapy for Malignant Diseases. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy255. | 0.9 | 16 |
| 115 | Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals. <i>Aids</i> , 2018, 32, 1995-2004. | 2.2 | 24 |
| 116 | Ageing and the evolution of comorbidities among HIV-positive individuals in a European cohort. <i>Aids</i> , 2018, 32, 2405-2416. | 2.2 | 83 |
| 117 | Body Mass Index and the Risk of Serious Non-AIDS Events and All-Cause Mortality in Treated HIV-Positive Individuals: D:A:D Cohort Analysis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 579-588. | 2.1 | 38 |
| 118 | Language used to convey HIV infection risk is important – Authors' reply. <i>Lancet HIV</i> , 2018, 5, e272. | 4.7 | 0 |
| 119 | Differences in response to antiretroviral therapy in HIV-positive patients being treated for tuberculosis in Eastern Europe, Western Europe and Latin America. <i>BMC Infectious Diseases</i> , 2018, 18, 191. | 2.9 | 5 |
| 120 | Using Clinical Research Networks to Assess Severity of an Emerging Influenza Pandemic. <i>Clinical Infectious Diseases</i> , 2018, 67, 341-349. | 5.8 | 6 |
| 121 | Computed tomography quantification of emphysema in people living with HIV and uninfected controls. <i>European Respiratory Journal</i> , 2018, 52, 1800296. | 6.7 | 15 |
| 122 | Persistent disparities in antiretroviral treatment (ART) coverage and virological suppression across Europe, 2004 to 2015. <i>Eurosurveillance</i> , 2018, 23, . | 7.0 | 12 |
| 123 | Predicting recovery from acute kidney injury in critically ill patients: development and validation of a prediction model. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , 2018, 20, 54-60. | 0.1 | 7 |
| 124 | Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μ L: secondary outcome results from a randomised controlled trial. <i>Lancet HIV</i> , 2017, 4, e105-e112. | 4.7 | 44 |
| 125 | Predictors of estimated glomerular filtration rate progression, stabilization or improvement after chronic renal impairment in HIV-positive individuals. <i>Aids</i> , 2017, 31, 1261-1270. | 2.2 | 16 |
| 126 | Late presentation of chronic viral hepatitis for medical care: a consensus definition. <i>BMC Medicine</i> , 2017, 15, 92. | 5.5 | 42 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Endothelial Damage Signals Refractory Acute Kidney Injury in Critically Ill Patients. <i>Shock</i> , 2017, 47, 696-701. | 2.1 | 17 |
| 128 | Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral) Tj ETQq0 0 0 ngBT /Overbook 10 Tf 5 | 2.1 | 17 |
| 129 | Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort. <i>Clinical Infectious Diseases</i> , 2017, 64, 1413-1421. | 5.8 | 66 |
| 130 | Are we successfully managing cardiovascular disease in people living with HIV?. <i>Current Opinion in HIV and AIDS</i> , 2017, 12, 594-603. | 3.8 | 10 |
| 131 | Incidental lung cancers and positive computed tomography images in people living with HIV. <i>Aids</i> , 2017, 31, 1973-1977. | 2.2 | 6 |
| 132 | Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials: Table 1.. <i>Clinical Infectious Diseases</i> , 2017, 64, 87-91. | 5.8 | 686 |
| 133 | Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx262. | 0.9 | 65 |
| 134 | Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study. <i>PLoS Medicine</i> , 2017, 14, e1002424. | 8.4 | 17 |
| 135 | Comparison of the Outcomes of Individuals With Medically Attended Influenza A and B Virus Infections Enrolled in 2 International Cohort Studies Over a 6-Year Period: 2009-2015. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx212. | 0.9 | 16 |
| 136 | Induced Hypothermia in Patients with Septic Shock and Ventilator-demanding Respiratory Failure. <i>Open Forum Infectious Diseases</i> , 2017, 4, S30-S30. | 0.9 | 0 |
| 137 | Neuropeptides and Airway Macromolecule Secretion. , 2017, , 447-464. | | 0 |
| 138 | Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral Therapy. <i>PLoS ONE</i> , 2016, 11, e0155100. | 2.5 | 150 |
| 139 | Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals?. <i>Aids</i> , 2016, 30, 1629-1637. | 2.2 | 8 |
| 140 | Improvements over time in short-term mortality following myocardial infarction in HIV-positive individuals. <i>Aids</i> , 2016, 30, 1583-1596. | 2.2 | 10 |
| 141 | Associations between HIV-RNA-based indicators and virological and clinical outcomes. <i>Aids</i> , 2016, 30, 1961-1972. | 2.2 | 10 |
| 142 | Copenhagen comorbidity in HIV infection (COCOMO) study: a study protocol for a longitudinal, non-interventional assessment of non-AIDS comorbidity in HIV infection in Denmark. <i>BMC Infectious Diseases</i> , 2016, 16, 713. | 2.9 | 61 |
| 143 | The per-protocol effect of immediate versus deferred antiretroviral therapy initiation. <i>Aids</i> , 2016, 30, 2659-2663. | 2.2 | 21 |
| 144 | Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw009. | 0.9 | 20 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Interleukin 6 Is a Stronger Predictor of Clinical Events Than High-Sensitivity C-Reactive Protein or D-Dimer During HIV Infection. <i>Journal of Infectious Diseases</i> , 2016, 214, 408-416. | 4.0 | 94 |
| 146 | Renal Impairment and Cardiovascular Disease in HIV-Positive Individuals: The D:A:D Study. <i>Journal of Infectious Diseases</i> , 2016, 214, 1212-1220. | 4.0 | 34 |
| 147 | Prediction of non-recovery from ventilator-demanding acute respiratory failure, ARDS and death using lung damage biomarkers: data from a 1200-patient critical care randomized trial. <i>Annals of Intensive Care</i> , 2016, 6, 114. | 4.6 | 14 |
| 148 | Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 171. | 7.4 | 1,076 |
| 149 | Predictive Value of Prostate Specific Antigen in a European HIV-positive Cohort: Does One Size Fit All?. <i>Antiviral Therapy</i> , 2016, 21, 529-534. | 1.0 | 8 |
| 150 | Longitudinal Analysis of the Associations between Antiretroviral Therapy, Viraemia and Immunosuppression with Lipid Levels: The D:A:D Study. <i>Antiviral Therapy</i> , 2016, 21, 495-506. | 1.0 | 20 |
| 151 | The cardiovascular risk management for people living with HIV in Europe. <i>Aids</i> , 2016, 30, 2505-2518. | 2.2 | 27 |
| 152 | Trends in Incidences and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virus-coinfected Individuals From 2001 to 2014: A Multicohort Study. <i>Clinical Infectious Diseases</i> , 2016, 63, 821-829. | 5.8 | 48 |
| 153 | Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration. <i>BMC Medicine</i> , 2016, 14, 61. | 5.5 | 100 |
| 154 | Identifying Key Drivers of the Impact of an HIV Cure Intervention in Sub-Saharan Africa. <i>Journal of Infectious Diseases</i> , 2016, 214, 73-79. | 4.0 | 13 |
| 155 | Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study. <i>Lancet HIV</i> , 2016, 3, e120-e131. | 4.7 | 53 |
| 156 | Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. <i>Lancet HIV</i> , 2016, 3, e23-e32. | 4.7 | 157 |
| 157 | An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 214-223. | 1.8 | 180 |
| 158 | A method to estimate the size and characteristics of HIV-positive populations using an individual-based stochastic simulation model. <i>Epidemiology</i> , 2015, 27, 1. | 2.7 | 6 |
| 159 | Thrombocytopenia and cancer risk during HIV infection. <i>Aids</i> , 2015, 29, 1425-1427. | 2.2 | 0 |
| 160 | Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSM. <i>Aids</i> , 2015, 29, 1855-1862. | 2.2 | 49 |
| 161 | Liver-related death among HIV/hepatitis C virus-co-infected individuals. <i>Aids</i> , 2015, 29, 1205-1215. | 2.2 | 46 |
| 162 | HIV resistance testing and detected drug resistance in Europe. <i>Aids</i> , 2015, 29, 1379-1389. | 2.2 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 163 | Projected Lifetime Healthcare Costs Associated with HIV Infection. PLoS ONE, 2015, 10, e0125018. | 2.5 | 47 |
| 164 | Major Challenges in Clinical Management of TB/HIV Coinfected Patients in Eastern Europe Compared with Western Europe and Latin America. PLoS ONE, 2015, 10, e0145380. | 2.5 | 19 |
| 165 | Factors Associated With Plasma IL-6 Levels During HIV Infection. Journal of Infectious Diseases, 2015, 212, 585-595. | 4.0 | 145 |
| 166 | Why <sc>START</sc>? Reflections that led to the conduct of this large long-term strategic <sc>HIV</sc> trial. HIV Medicine, 2015, 16, 1-9. | 2.2 | 26 |
| 167 | Sustainable HIV treatment in Africa through viral-load-informed differentiated care. Nature, 2015, 528, S68-S76. | 27.8 | 141 |
| 168 | Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study. PLoS Medicine, 2015, 12, e1001809. | 8.4 | 119 |
| 169 | Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. New England Journal of Medicine, 2015, 373, 795-807. | 27.0 | 2,232 |
| 170 | When is the best time to initiate antiretroviral therapy?. Lancet HIV, the, 2015, 2, e312-e313. | 4.7 | 1 |
| 171 | Profound Endothelial Damage Predicts Impending Organ Failure and Death in Sepsis. Seminars in Thrombosis and Hemostasis, 2015, 41, 016-025. | 2.7 | 79 |
| 172 | Hepatitis C seroconversions in <sc>HIV</sc> infection across Europe: which regions and patient groups are affected?. Liver International, 2015, 35, 2384-2391. | 3.9 | 33 |
| 173 | Invasive Candida Infections and the Harm From Antibacterial Drugs in Critically Ill Patients. Critical Care Medicine, 2015, 43, 594-602. | 0.9 | 39 |
| 174 | Cancer Risk and Use of Protease Inhibitor or Nonnucleoside Reverse Transcriptase Inhibitor-Based Combination Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 568-577. | 2.1 | 41 |
| 175 | The Vancouver Consensus: antiretroviral medicines, medical evidence, and political will. Lancet, The, 2015, 386, 505-507. | 13.7 | 24 |
| 176 | Mild induced hypothermia: Effects on sepsis-related coagulopathy -results from a randomized controlled trial. Thrombosis Research, 2015, 135, 175-182. | 1.7 | 13 |
| 177 | Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. Eurosurveillance, 2015, 20, . | 7.0 | 70 |
| 178 | Major challenges in clinical management of TB/HIV co-infected patients in Eastern Europe compared with Western Europe and Latin America. Journal of the International AIDS Society, 2014, 17, 19505. | 3.0 | 8 |
| 179 | Potential Future Impact of a Partially Effective HIV Vaccine in a Southern African Setting. PLoS ONE, 2014, 9, e107214. | 2.5 | 20 |
| 180 | Determinants of IL-6 levels during HIV infection. Journal of the International AIDS Society, 2014, 17, 19482. | 3.0 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 181 | The prevalence and predictive value of dipstick urine protein in HIV-positive persons in Europe. <i>Journal of the International AIDS Society</i> , 2014, 17, 19561. | 3.0 | 1 |
| 182 | Elevation in Liver Transaminase (ALT-flares) in Transplant (TX) Recipients: Risk factors and Consequences. <i>Open Forum Infectious Diseases</i> , 2014, 1, S26-S26. | 0.9 | 0 |
| 183 | Roundtable discussion: how lessons learned from HIV can inform the global response to viral hepatitis. <i>BMC Infectious Diseases</i> , 2014, 14, S18. | 2.9 | 5 |
| 184 | HIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspective. <i>BMC Infectious Diseases</i> , 2014, 14, S13. | 2.9 | 19 |
| 185 | Novel Biomarkers of Infection in Critically Ill Cancer Patients. <i>Critical Care Medicine</i> , 2014, 42, 2632-2633. | 0.9 | 0 |
| 186 | Prognostic Value of Vitamin D Level for All-cause Mortality, and Association With Inflammatory Markers, in HIV-infected Persons. <i>Journal of Infectious Diseases</i> , 2014, 210, 234-243. | 4.0 | 42 |
| 187 | Predicted levels of HIV drug resistance. <i>Aids</i> , 2014, 28, S15-S23. | 2.2 | 45 |
| 188 | Relationship between inflammatory and coagulation biomarkers and cardiac autonomic function in HIV-infected individuals. <i>Biomarkers in Medicine</i> , 2014, 8, 1073-1083. | 1.4 | 9 |
| 189 | Short- and long-term mortality and causes of death in HIV/tuberculosis patients in Europe. <i>European Respiratory Journal</i> , 2014, 43, 166-177. | 6.7 | 30 |
| 190 | People with HIV are at increased risk of acute myocardial infarction. <i>Evidence-based Nursing</i> , 2014, 17, 43-44. | 0.2 | 0 |
| 191 | Antiretroviral therapy recommendations for the global community. <i>Aids</i> , 2014, 28, 939-941. | 2.2 | 3 |
| 192 | Antiretroviral therapy, immune suppression and renal impairment in HIV-positive persons. <i>Current Opinion in HIV and AIDS</i> , 2014, 9, 41-47. | 3.8 | 16 |
| 193 | Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease. <i>Aids</i> , 2014, 28, 1791-1796. | 2.2 | 25 |
| 194 | Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease. <i>Aids</i> , 2014, 28, 2565-2571. | 2.2 | 9 |
| 195 | Antiretroviral dose reduction: good for patients and rollout. <i>Lancet, The</i> , 2014, 383, 1442-1443. | 13.7 | 3 |
| 196 | Multi-drug-resistant tuberculosis in HIV positive patients in Eastern Europe. <i>Journal of Infection</i> , 2014, 68, 259-263. | 3.3 | 38 |
| 197 | Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysis. <i>Lancet HIV,the</i> , 2014, 1, e85-e93. | 4.7 | 39 |
| 198 | Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. <i>Lancet, The</i> , 2014, 384, 241-248. | 13.7 | 767 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 199 | Update on HIV in Western Europe. <i>Current HIV/AIDS Reports</i> , 2014, 11, 177-185. | 3.1 | 23 |
| 200 | Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study. <i>BMC Nephrology</i> , 2014, 15, 51. | 1.8 | 10 |
| 201 | Determinants of developing widened spatial QRS-T angle in HIV-infected individuals: Results from the Strategies for Management of Antiretroviral Therapy [SMART] Study. <i>Journal of Electrocardiology</i> , 2014, 47, 264-271. | 0.9 | 3 |
| 202 | Biomarkers of inflammation, coagulation and microbial translocation in HIV/HCV co-infected patients in the SMART study. <i>Journal of Clinical Virology</i> , 2014, 60, 295-300. | 3.1 | 22 |
| 203 | Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. <i>The Lancet Global Health</i> , 2014, 2, e23-e34. | 6.3 | 188 |
| 204 | Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons. <i>Aids</i> , 2014, 28, 187-199. | 2.2 | 60 |
| 205 | Increased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosis. <i>Aids</i> , 2014, 28, 577-587. | 2.2 | 11 |
| 206 | Deteriorating renal function and clinical outcomes in HIV-positive persons. <i>Aids</i> , 2014, 28, 727-737. | 2.2 | 25 |
| 207 | Immuno-Virological Discordance and the Risk of Non-AIDS and AIDS Events in a Large Observational Cohort of HIV-Patients in Europe. <i>PLoS ONE</i> , 2014, 9, e87160. | 2.5 | 35 |
| 208 | Factors Associated with D-Dimer Levels in HIV-Infected Individuals. <i>PLoS ONE</i> , 2014, 9, e90978. | 2.5 | 60 |
| 209 | Outcomes of Influenza A(H1N1)pdm09 Virus Infection: Results from Two International Cohort Studies. <i>PLoS ONE</i> , 2014, 9, e101785. | 2.5 | 31 |
| 210 | Cost-Effectiveness of HIV Drug Resistance Testing to Inform Switching to Second Line Antiretroviral Therapy in Low Income Settings. <i>PLoS ONE</i> , 2014, 9, e109148. | 2.5 | 24 |
| 211 | When to start antiretroviral therapy: the need for an evidence base during early HIV infection. <i>BMC Medicine</i> , 2013, 11, 148. | 5.5 | 30 |
| 212 | Contribution of Genetic Background, Traditional Risk Factors, and HIV-Related Factors to Coronary Artery Disease Events in HIV-Positive Persons. <i>Clinical Infectious Diseases</i> , 2013, 57, 112-121. | 5.8 | 56 |
| 213 | Are antiretrovirals enough for people living with HIV?. <i>Lancet, The</i> , 2013, 382, 1466-1467. | 13.7 | 3 |
| 214 | Electrocardiographic Spatial QRS-T Angle and Incident Cardiovascular Disease in HIV-Infected Patients (from the Strategies for the Management of Antiretroviral Therapy [SMART] Study). <i>American Journal of Cardiology</i> , 2013, 111, 118-124. | 1.6 | 6 |
| 215 | Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. <i>Clinical Trials</i> , 2013, 10, S5-S36. | 1.6 | 100 |
| 216 | CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. <i>Aids</i> , 2013, 27, 907-918. | 2.2 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 217 | Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events. <i>Aids</i> , 2013, 27, 407-415. | 2.2 | 89 |
| 218 | Associations between immune depression and cardiovascular events in HIV infection. <i>Aids</i> , 2013, 27, 2735-2748. | 2.2 | 51 |
| 219 | TB Meningitis in HIV-Positive Patients in Europe and Argentina: Clinical Outcome and Factors Associated with Mortality. <i>BioMed Research International</i> , 2013, 2013, 1-9. | 1.9 | 10 |
| 220 | Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). <i>PLoS Medicine</i> , 2013, 10, e1001510. | 8.4 | 256 |
| 221 | Association Between Antiretroviral Exposure and Renal Impairment Among HIV-Positive Persons With Normal Baseline Renal Function: the D:A:D Study. <i>Journal of Infectious Diseases</i> , 2013, 207, 1359-1369. | 4.0 | 271 |
| 222 | The natural history of HIV infection. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 1. | 3.8 | 50 |
| 223 | Editorial Commentary: Universal Antiretroviral Therapy for HIV Infection?. <i>Clinical Infectious Diseases</i> , 2013, 57, 888-890. | 5.8 | 11 |
| 224 | Antiretroviral Drug-Related Liver Mortality Among HIV-Positive Persons in the Absence of Hepatitis B or C Virus Coinfection: The Data Collection on Adverse Events of Anti-HIV Drugs Study. <i>Clinical Infectious Diseases</i> , 2013, 56, 870-879. | 5.8 | 42 |
| 225 | The Incidence of AIDS-Defining Illnesses at a Current CD4 Count ≥ 200 Cells/ μ L in the Post-Combination Antiretroviral Therapy Era. <i>Clinical Infectious Diseases</i> , 2013, 57, 1038-1047. | 5.8 | 92 |
| 226 | Transmission of Drug Resistant HIV and Its Potential Impact on Mortality and Treatment Outcomes in Resource-Limited Settings. <i>Journal of Infectious Diseases</i> , 2013, 207, S57-S62. | 4.0 | 64 |
| 227 | Further research needed to support a policy of antiretroviral therapy as an HIV prevention initiative. <i>Antiviral Therapy</i> , 2013, 18, 285-7. | 1.0 | 8 |
| 228 | Predicting risk of cancer during HIV infection. <i>Aids</i> , 2013, 27, 1433-1441. | 2.2 | 158 |
| 229 | Platelet count kinetics following interruption of antiretroviral treatment. <i>Aids</i> , 2013, 27, 59-68. | 2.2 | 13 |
| 230 | Association Between ALT Level and the Rate of Cardio/Cerebrovascular Events in HIV-Positive Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, 456-463. | 2.1 | 13 |
| 231 | Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study. <i>BMC Infectious Diseases</i> , 2013, 13, 471. | 2.9 | 68 |
| 232 | Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-Related Death in HIV/Viral Hepatitis Coinfected Patients. <i>PLoS ONE</i> , 2013, 8, e64283. | 2.5 | 25 |
| 233 | Feasibility and Effectiveness of Indicator Condition-Guided Testing for HIV: Results from HIDES I (HIV) Tj ETQq1 1 0.784314 rgBT /Overlo | 2.5 | 145 |
| 234 | Increased HIV Incidence in Men Who Have Sex with Men Despite High Levels of ART-Induced Viral Suppression: Analysis of an Extensively Documented Epidemic. <i>PLoS ONE</i> , 2013, 8, e55312. | 2.5 | 197 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 235 | The Association between Serum Biomarkers and Disease Outcome in Influenza A(H1N1)pdm09 Virus Infection: Results of Two International Observational Cohort Studies. PLoS ONE, 2013, 8, e57121. | 2.5 | 54 |
| 236 | The Potential of Antimicrobials to Induce Thrombocytopenia in Critically Ill Patients: Data from a Randomized Controlled Trial. PLoS ONE, 2013, 8, e81477. | 2.5 | 16 |
| 237 | â€œEâ€•is for everything else, not least for expanding HIV testing in Europe. Bulletin of the World Health Organization, 2012, 90, 634-634. | 3.3 | 2 |
| 238 | Projected life expectancy of people with HIV according to timing of diagnosis. Aids, 2012, 26, 335-343. | 2.2 | 350 |
| 239 | Kidney failure related to broad-spectrum antibiotics in critically ill patients: secondary end point results from a 1200 patient randomised trial. BMJ Open, 2012, 2, e000635. | 1.9 | 77 |
| 240 | Aging with HIV in Africa. Aids, 2012, 26, S1-S5. | 2.2 | 89 |
| 241 | HIV Replication, Inflammation, and the Effect of Starting Antiretroviral Therapy on Plasma Asymmetric Dimethylarginine, a Novel Marker of Endothelial Dysfunction. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, 128-134. | 2.1 | 21 |
| 242 | Long-term exposure to combination antiretroviral therapy and risk of death from specific causes. Aids, 2012, 26, 315-323. | 2.2 | 35 |
| 243 | System to classify cause of deaths in HIV-positive persons. Aids, 2012, 26, 1835-1836. | 2.2 | 5 |
| 244 | Refinement of prompts for rapid response teams*. Critical Care Medicine, 2012, 40, 2241-2242. | 0.9 | 0 |
| 245 | The Clinical Benefits of Antiretroviral Therapy in Severely Immunocompromised HIV-1-Infected Patients with and without Complete Viral Suppression. Antiviral Therapy, 2012, 17, 1291-1300. | 1.0 | 10 |
| 246 | Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. Aids, 2012, 26, 1917-1926. | 2.2 | 62 |
| 247 | Dampening the effect of drug resistance in HIV: a leap forward. Lancet Infectious Diseases, The, 2012, 12, 91-92. | 9.1 | 3 |
| 248 | Benchmarking HIV health care: from individual patient care to health care evaluation. An example from the EuroSIDA study. BMC Infectious Diseases, 2012, 12, 229. | 2.9 | 9 |
| 249 | Partners of people on ART - a New Evaluation of the Risks (The PARTNER study): design and methods. BMC Public Health, 2012, 12, 296. | 2.9 | 30 |
| 250 | Regional Differences in AIDS and Non-AIDS Related Mortality in HIV-Positive Individuals across Europe and Argentina: The EuroSIDA Study. PLoS ONE, 2012, 7, e41673. | 2.5 | 32 |
| 251 | Hepatitis B and C Co-Infection Are Independent Predictors of Progressive Kidney Disease in HIV-Positive, Antiretroviral-Treated Adults. PLoS ONE, 2012, 7, e40245. | 2.5 | 66 |
| 252 | Cost-Effectiveness of Tenofovir Instead of Zidovudine for Use in First-Line Antiretroviral Therapy in Settings without Virological Monitoring. PLoS ONE, 2012, 7, e42834. | 2.5 | 14 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 253 | Inflammation, Coagulation and Cardiovascular Disease in HIV-Infected Individuals. PLoS ONE, 2012, 7, e44454. | 2.5 | 456 |
| 254 | Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Journal of the International AIDS Society, 2012, 15, 17426. | 3.0 | 54 |
| 255 | HIV Therapies and the Kidney: Some Good, Some Not So Good?. Current HIV/AIDS Reports, 2012, 9, 111-120. | 3.1 | 14 |
| 256 | Factors associated with the development of cytomegalovirus infection following solid organ transplantation. Scandinavian Journal of Infectious Diseases, 2011, 43, 360-365. | 1.5 | 23 |
| 257 | Prevention of HIV-1 Infection with Antiretroviral Therapy. New England Journal of Medicine, 2011, 365, 1934-1935. | 27.0 | 56 |
| 258 | The metabolic syndrome in HIV. Best Practice and Research in Clinical Endocrinology and Metabolism, 2011, 25, 479-486. | 4.7 | 26 |
| 259 | Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infectious Diseases, The, 2011, 11, 363-371. | 9.1 | 345 |
| 260 | Predictors of having a resistance test following confirmed virological failure of combination antiretroviral therapy: data from EuroSIDA. Antiviral Therapy, 2011, 16, 781-785. | 1.0 | 1 |
| 261 | Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations. Aids, 2011, 25, 367-377. | 2.2 | 62 |
| 262 | Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. Aids, 2011, 25, 1305-1315. | 2.2 | 157 |
| 263 | Elevated triglycerides and risk of myocardial infarction in HIV-positive persons. Aids, 2011, 25, 1497-1504. | 2.2 | 39 |
| 264 | Hepatitis delta in HIV-infected individuals in Europe. Aids, 2011, 25, 1987-1992. | 2.2 | 79 |
| 265 | Changes in Inflammatory and Coagulation Biomarkers: A Randomized Comparison of Immediate versus Deferred Antiretroviral Therapy in Patients With HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 36-43. | 2.1 | 142 |
| 266 | Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: A randomized trial*. Critical Care Medicine, 2011, 39, 2048-2058. | 0.9 | 336 |
| 267 | Tuberculosis among HIV-positive patients across Europe. Aids, 2011, 25, 1505-1513. | 2.2 | 19 |
| 268 | Antibiotics in intensive care: Too little or too much?*. Critical Care Medicine, 2011, 39, 1849-1851. | 0.9 | 14 |
| 269 | The Coding Causes of Death in HIV (CoDe) Project. Epidemiology, 2011, 22, 516-523. | 2.7 | 129 |
| 270 | A Standardized Algorithm for Determining the Underlying Cause of Death in HIV Infection as AIDS or non-AIDS Related: Results from the EuroSIDA Study. HIV Clinical Trials, 2011, 12, 109-117. | 2.0 | 29 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 271 | Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings. <i>Aids</i> , 2011, 25, 843-850. | 2.2 | 79 |
| 272 | Haemoglobin and Anaemia in the Smart Study. <i>Antiviral Therapy</i> , 2011, 16, 329-337. | 1.0 | 12 |
| 273 | Hyaluronic Acid Levels Predict Increased Risk of Non-Aids Death in Hepatitis-Coinfected Persons Interrupting Antiretroviral Therapy in the Smart Study. <i>Antiviral Therapy</i> , 2011, 16, 667-675. | 1.0 | 16 |
| 274 | Prevalence and prognostic significance of ECG abnormalities in HIV-infected patients: results from the Strategies for Management of Antiretroviral Therapy study. <i>Journal of Electrocardiology</i> , 2011, 44, 779-785. | 0.9 | 47 |
| 275 | Cardiovascular implications from untreated human immunodeficiency virus infection. <i>European Heart Journal</i> , 2011, 32, 945-951. | 2.2 | 68 |
| 276 | A376S in the Connection Subdomain of HIV-1 Reverse Transcriptase Confers Increased Risk of Virological Failure to Nevirapine Therapy. <i>Journal of Infectious Diseases</i> , 2011, 204, 741-752. | 4.0 | 19 |
| 277 | Can Linear Regression Modeling Help Clinicians in the Interpretation of Genotypic Resistance Data? An Application to Derive a Lopinavir-Score. <i>PLoS ONE</i> , 2011, 6, e25665. | 2.5 | 5 |
| 278 | Triple-Class Virologic Failure in HIV-Infected Patients Undergoing Antiretroviral Therapy for Up to 10 Years. <i>Archives of Internal Medicine</i> , 2010, 170, 410-419. | 3.8 | 42 |
| 279 | Dialysis and Renal Transplantation in HIV-Infected Patients: a European Survey. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 55, 582-589. | 2.1 | 42 |
| 280 | High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. <i>Aids</i> , 2010, 24, 427-435. | 2.2 | 76 |
| 281 | Biomarkers in HIV disease. <i>Current Opinion in HIV and AIDS</i> , 2010, 5, 459-462. | 3.8 | 9 |
| 282 | Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption. <i>Aids</i> , 2010, 24, 857-865. | 2.2 | 59 |
| 283 | Estimated average annual rate of change of CD4+ T-cell counts in patients on combination antiretroviral therapy. <i>Antiviral Therapy</i> , 2010, 15, 563-570. | 1.0 | 12 |
| 284 | Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study. <i>Aids</i> , 2010, 24, 1537-1548. | 2.2 | 381 |
| 285 | HBV or HCV Coinfections and Risk of Myocardial Infarction in HIV-Infected Individuals: The D:A:D Cohort Study. <i>Antiviral Therapy</i> , 2010, 15, 1077-1086. | 1.0 | 35 |
| 286 | Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. <i>Cancer</i> , 2010, 116, 5306-5315. | 4.1 | 120 |
| 287 | Regulatory impediments jeopardizing the conduct of clinical trials in Europe funded by the National Institutes of Health. <i>Clinical Trials</i> , 2010, 7, 705-718. | 1.6 | 27 |
| 288 | Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. <i>Journal of Infectious Diseases</i> , 2010, 201, 318-330. | 4.0 | 575 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 289 | Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 548-555. | 3.0 | 51 |
| 290 | Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010, 17, 491-501. | 2.8 | 309 |
| 291 | Rescue of Severely Immunocompromised HIV-Positive Persons. <i>Journal of Infectious Diseases</i> , 2010, 202, 1467-1469. | 4.0 | 1 |
| 292 | Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. <i>Aids</i> , 2010, 24, 1667-1678. | 2.2 | 353 |
| 293 | Serious Fatal and Nonfatal Non-AIDS-Defining Illnesses in Europe. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 55, 262-270. | 2.1 | 243 |
| 294 | Rate of Accumulation of Thymidine Analogue Mutations in Patients Continuing to Receive Virologically Failing Regimens Containing Zidovudine or Stavudine: Implications for Antiretroviral Therapy Programs in Resource-Limited Settings. <i>Journal of Infectious Diseases</i> , 2009, 200, 687-697. | 4.0 | 56 |
| 295 | Use of Risk Equations for Predicting Disease Progression in HIV Infection. <i>Clinical Infectious Diseases</i> , 2009, 48, 951-953. | 5.8 | 4 |
| 296 | Activation and Coagulation Biomarkers Are Independent Predictors of the Development of Opportunistic Disease in Patients with HIV Infection. <i>Journal of Infectious Diseases</i> , 2009, 200, 973-983. | 4.0 | 140 |
| 297 | Presence of the Metabolic Syndrome Is Not a Better Predictor of Cardiovascular Disease Than the Sum of Its Components in HIV-Infected Individuals: Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) study. <i>Diabetes Care</i> , 2009, 32, 474-480. | 8.6 | 33 |
| 298 | Cost-effectiveness of Strategies for Monitoring the Response to Antiretroviral Therapy in Resource-Limited Settings. <i>Archives of Internal Medicine</i> , 2009, 169, 904. | 3.8 | 2 |
| 299 | Uncertainty as to Whether the Use of Antiretroviral Therapy for Persons Recently Infected with HIV Has a Favorable Risk-Benefit Ratio. <i>Clinical Infectious Diseases</i> , 2009, 48, 1162-1162. | 5.8 | 6 |
| 300 | Reply to Pascual Pareja et al.. <i>Journal of Infectious Diseases</i> , 2009, 199, 1557-1557. | 4.0 | 1 |
| 301 | Diabetes Mellitus, Preexisting Coronary Heart Disease, and the Risk of Subsequent Coronary Heart Disease Events in Patients Infected With Human Immunodeficiency Virus. <i>Circulation</i> , 2009, 119, 805-811. | 1.6 | 88 |
| 302 | Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina. <i>Aids</i> , 2009, 23, 2485-2495. | 2.2 | 36 |
| 303 | Procalcitonin monitoring in trauma intensive care patients: How helpful is it?*. <i>Critical Care Medicine</i> , 2009, 37, 2093-2094. | 0.9 | 6 |
| 304 | Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. <i>Aids</i> , 2009, 23, 1689-1699. | 2.2 | 69 |
| 305 | Incidence and Risk Factors of HIV-Related Non-Hodgkin's Lymphoma in the era of Combination Antiretroviral Therapy: A European Multicohort Study. <i>Antiviral Therapy</i> , 2009, 14, 1065-1074. | 1.0 | 92 |
| 306 | Hepatitis C Virus Coinfection Does Not Influence the CD4 Cell Recovery in HIV-1-Infected Patients With Maximum Virologic Suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 50, 457-463. | 2.1 | 49 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 307 | The Procalcitonin And Survival Study (PASS) – A Randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients. <i>BMC Infectious Diseases</i> , 2008, 8, 91. | 2.9 | 37 |
| 308 | In vivo study of experimental pneumococcal meningitis using magnetic resonance imaging. <i>BMC Medical Imaging</i> , 2008, 8, 1. | 2.7 | 27 |
| 309 | The elusive search for an HIV vaccine – And what to do meanwhile. <i>Vaccine</i> , 2008, 26, 6491-6493. | 3.8 | 1 |
| 310 | Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. <i>Lancet</i> , The, 2008, 371, 1417-1426. | 13.7 | 809 |
| 311 | Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. <i>Lancet</i> , The, 2008, 371, 1443-1451. | 13.7 | 158 |
| 312 | Monitoring of antiretroviral therapy in low-resource settings – Authors' reply. <i>Lancet</i> , The, 2008, 372, 289. | 13.7 | 2 |
| 313 | Abacavir and increased risk of myocardial infarction – Authors' reply. <i>Lancet</i> , The, 2008, 372, 804-805. | 13.7 | 13 |
| 314 | Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/ μ l in the era of cART. <i>Scandinavian Journal of Infectious Diseases</i> , 2008, 40, 908-913. | 1.5 | 2 |
| 315 | Procalcitonin in liver transplant patients – yet another stone turned. <i>Critical Care</i> , 2008, 12, 108. | 5.8 | 4 |
| 316 | Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study. <i>Aids</i> , 2008, 22, 2187-2198. | 2.2 | 37 |
| 317 | Incidence of pancreatitis in HIV-infected patients, and the association with antiretroviral therapy. <i>Aids</i> , 2008, 22, 997-998. | 2.2 | 6 |
| 318 | HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. <i>Aids</i> , 2008, 22, 2143-2153. | 2.2 | 207 |
| 319 | Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. <i>Aids</i> , 2008, 22, 2279-2289. | 2.2 | 64 |
| 320 | Transmitted Drug Resistant HIV-1 and Association With Virologic and CD4 Cell Count Response to Combination Antiretroviral Therapy in the EuroSIDA Study. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2008, 48, 324-333. | 2.1 | 46 |
| 321 | Inferior Clinical Outcome of the CD4+ Cell Count – Guided Antiretroviral Treatment Interruption Strategy in the SMART Study: Role of CD4+ Cell Counts and HIV RNA Levels during Follow-up. <i>Journal of Infectious Diseases</i> , 2008, 197, 1145-1155. | 4.0 | 191 |
| 322 | Impact of Bacteremia on the Pathogenesis of Experimental Pneumococcal Meningitis. <i>Journal of Infectious Diseases</i> , 2008, 197, 235-244. | 4.0 | 34 |
| 323 | The role of HIV in serious diseases other than AIDS. <i>Aids</i> , 2008, 22, 2409-2418. | 2.2 | 227 |
| 324 | Opportunistic Disease and Mortality in Patients Coinfected with Hepatitis B or C Virus in the Strategic Management of Antiretroviral Therapy (SMART) Study. <i>Clinical Infectious Diseases</i> , 2008, 47, 1468-1475. | 5.8 | 53 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 325 | Pneumonia in HIV-infected Persons. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 630-636. | 5.6 | 104 |
| 326 | Spontaneous Viral Clearance, Viral Load, and Genotype Distribution of Hepatitis C Virus (HCV) in HIV-Infected Patients with Anti-HCV Antibodies in Europe. Journal of Infectious Diseases, 2008, 198, 1337-1344. | 4.0 | 145 |
| 327 | Guidelines for managing cardiovascular risk: an evolving area. Current Opinion in HIV and AIDS, 2008, 3, 205-206. | 3.8 | 4 |
| 328 | The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study. Aids, 2008, 22, 47-56. | 2.2 | 38 |
| 329 | Response to combination antiretroviral therapy: variation by age. Aids, 2008, 22, 1463-1473. | 2.2 | 188 |
| 330 | Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. Aids, 2008, 22, 367-376. | 2.2 | 43 |
| 331 | Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?. Aids, 2008, 22, 2381-2390. | 2.2 | 30 |
| 332 | Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection. PLoS Medicine, 2008, 5, e203. | 8.4 | 1,398 |
| 333 | The EuroSIDA Study: Regional Differences in the HIV-1 Epidemic and Treatment Response to Antiretroviral Therapy among HIV-infected Patients across Europe - A Review of Published Results. Central European Journal of Public Health, 2008, 16, 99-105. | 1.1 | 15 |
| 334 | EuroSIDA: a prospective observational study of chronic HIV infection across the European continent. , 2008, , 195-212. | | 0 |
| 335 | ART Failure and Strategies for Switching ART Regimens in Europe. Central European Journal of Public Health, 2008, 16, 141-144. | 1.1 | 0 |
| 336 | Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antiviral Therapy, 2008, 13, 177-87. | 1.0 | 95 |
| 337 | Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response. Antiviral Therapy, 2008, 13, 399-407. | 1.0 | 7 |
| 338 | Interruption of Antiretroviral Therapy and Risk of Cardiovascular Disease in Persons with HIV-1 Infection: Exploratory Analyses from the SMART Trial. Antiviral Therapy, 2008, 13, 177-188. | 1.0 | 191 |
| 339 | Modelled in vivo HIV Fitness under drug Selective Pressure and Estimated Genetic Barrier Towards Resistance are Predictive for Virological Response. Antiviral Therapy, 2008, 13, 399-408. | 1.0 | 17 |
| 340 | Incidence of abacavir hypersensitivity reactions in EuroSIDA. Antiviral Therapy, 2008, 13, 687-696. | 1.0 | 14 |
| 341 | Class of Antiretroviral Drugs and the Risk of Myocardial Infarction. New England Journal of Medicine, 2007, 356, 1723-1735. | 27.0 | 1,393 |
| 342 | A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men. International Journal of Epidemiology, 2007, 36, 1309-1318. | 1.9 | 22 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 343 | Impact of HIV-1 Reverse Transcriptase Polymorphism F214L on Virological Response to Thymidine Analogue-Based Regimens in Antiretroviral Therapy (ART)-Naive and ART-Experienced Patients. <i>Journal of Infectious Diseases</i> , 2007, 196, 1180-1190. | 4.0 | 12 |
| 344 | When should antiretroviral therapy for HIV be started?. <i>BMJ: British Medical Journal</i> , 2007, 334, 76-78. | 2.3 | 68 |
| 345 | Clinical outcomes in clinical trials of anti-HIV treatment. <i>Future HIV Therapy</i> , 2007, 1, 251-258. | 0.4 | 1 |
| 346 | Chronic renal failure among HIV-1-infected patients. <i>Aids</i> , 2007, 21, 1119-1127. | 2.2 | 192 |
| 347 | Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score. <i>Aids</i> , 2007, 21, 1867-1875. | 2.2 | 38 |
| 348 | Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. <i>Aids</i> , 2007, 21, 721-732. | 2.2 | 85 |
| 349 | The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors. <i>Aids</i> , 2007, 21, 2033-2042. | 2.2 | 15 |
| 350 | Meta-analysis of procalcitonin for sepsis detection. <i>Lancet Infectious Diseases</i> , The, 2007, 7, 499-500. | 9.1 | 8 |
| 351 | Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count ≥ 300 cells/?L who were assigned to 7.5 MIU interleukin-2. <i>HIV Medicine</i> , 2007, 8, 112-123. | 2.2 | 7 |
| 352 | Pharmacokinetics of Two Randomized Trials Evaluating the Safety and Efficacy of Indinavir, Saquinavir and Lopinavir in Combination with Low-Dose Ritonavir: The MaxCmin1 and 2 Trials. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2007, 101, 339-344. | 2.5 | 11 |
| 353 | Risk of Discontinuation of Nevirapine due to Toxicities in Antiretroviral-Naive and -Experienced HIV-Infected patients with High and Low CD4 ⁺ T-cell Counts. <i>Antiviral Therapy</i> , 2007, 12, 325-334. | 1.0 | 35 |
| 354 | HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. <i>Lancet</i> , The, 2006, 368, 451-458. | 13.7 | 209 |
| 355 | The CD4 lymphocyte count and risk of clinical progression. <i>Current Opinion in HIV and AIDS</i> , 2006, 1, 43-49. | 3.8 | 56 |
| 356 | Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. <i>Aids</i> , 2006, 20, 1141-1150. | 2.2 | 39 |
| 357 | Issues in the design of trials comparing management strategies for heavily pretreated patients. <i>Current Opinion in HIV and AIDS</i> , 2006, 1, 476-481. | 3.8 | 1 |
| 358 | Influence of the blood bacterial load on the meningeal inflammatory response in <i>Streptococcus pneumoniae</i> meningitis. <i>BMC Infectious Diseases</i> , 2006, 6, 78. | 2.9 | 14 |
| 359 | Regional Changes Over Time in Initial Virologic Response Rates to Combination Antiretroviral Therapy Across Europe. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 42, 229-237. | 2.1 | 40 |
| 360 | Factors Associated with the Development of Opportunistic Infections in HIV-1-Infected Adults with High CD4+Cell Counts: A EuroSIDA Study. <i>Journal of Infectious Diseases</i> , 2006, 194, 633-641. | 4.0 | 70 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 361 | Limited but increasing use of treatment for hepatitis C across Europe in patients coinfecting with HIV and hepatitis C. <i>Scandinavian Journal of Infectious Diseases</i> , 2006, 38, 1092-1097. | 1.5 | 15 |
| 362 | Evaluation of anti-pneumococcal capsular antibodies as adjunctive therapy in experimental pneumococcal meningitis. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 1291-1294. | 3.0 | 4 |
| 363 | Liver-Related Deaths in Persons Infected With the Human Immunodeficiency Virus. <i>Archives of Internal Medicine</i> , 2006, 166, 1632. | 3.8 | 1,004 |
| 364 | The impact of antiretroviral therapy on AIDS and survival. <i>Journal of HIV Therapy</i> , 2006, 11, 36-8. | 0.6 | 11 |
| 365 | Impact of Lamivudine on the Risk of Liver-Related Death in 2,041 Hbsag- and HIV-Positive Individuals: Results from An Inter-Cohort Analysis. <i>Antiviral Therapy</i> , 2006, 11, 567-574. | 1.0 | 38 |
| 366 | HIV-1 Subtypes and Response to Combination Antiretroviral Therapy in Europe. <i>Antiviral Therapy</i> , 2006, 11, 707-716. | 1.0 | 52 |
| 367 | Impact of Coinfection With HIV-1 and GB Virus C in Patients Receiving a Ritonavir-Boosted HAART Regimen: A Substudy to the MaxCmin1 Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 40, 378-380. | 2.1 | 6 |
| 368 | Blocking of leukocyte accumulation in the cerebrospinal fluid augments bacteremia and increases lethality in experimental pneumococcal meningitis. <i>Journal of Neuroimmunology</i> , 2005, 166, 126-131. | 2.3 | 35 |
| 369 | Genetic evolution of HIV in patients remaining on a stable HAART regimen despite insufficient viral suppression. <i>Scandinavian Journal of Infectious Diseases</i> , 2005, 37, 890-901. | 1.5 | 41 |
| 370 | Decline in Esophageal Candidiasis and Use of Antimycotics in European Patients with HIV. <i>American Journal of Gastroenterology</i> , 2005, 100, 1446-1454. | 0.4 | 29 |
| 371 | Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. <i>Aids</i> , 2005, 19, 593-601. | 2.2 | 472 |
| 372 | Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?. <i>Aids</i> , 2005, 19, 2117-2125. | 2.2 | 109 |
| 373 | Influence of Hepatitis C Virus Infection on HIV Disease Progression and Response to Highly Active Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2005, 192, 992-1002. | 4.0 | 362 |
| 374 | SHORT STATEMENT OF THE FIRST EUROPEAN CONSENSUS CONFERENCE ON THE TREATMENT OF CHRONIC HEPATITIS B AND C IN HIV CO-INFECTED PATIENTS. <i>Journal of Hepatology</i> , 2005, 42, 615-624. | 3.7 | 357 |
| 375 | Corrigendum to "SHORT STATEMENT OF THE FIRST EUROPEAN CONSENSUS CONFERENCE ON THE TREATMENT OF CHRONIC HEPATITIS B AND C IN HIV CO-INFECTED PATIENTS" [Hepatology 42 (2005) 615-624]. <i>Journal of Hepatology</i> , 2005, 43, 1098. | 3.7 | 1 |
| 376 | Prospective Evaluation of a Whole-Blood Test Using <i>Mycobacterium tuberculosis</i> -Specific Antigens ESAT-6 and CFP-10 for Diagnosis of Active Tuberculosis. <i>Vaccine Journal</i> , 2005, 12, 491-496. | 3.1 | 164 |
| 377 | Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection?. <i>Antiviral Therapy</i> , 2005, 10, 779-90. | 1.0 | 5 |
| 378 | A Randomized Trial to Evaluate Lopinavir/Ritonavir versus Saquinavir/Ritonavir in HIV-1-Infected Patients: The Maxcmin2 Trial. <i>Antiviral Therapy</i> , 2005, 10, 735-743. | 1.0 | 51 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 379 | Predictors of Hypertension and Changes of Blood Pressure in HIV-Infected Patients. <i>Antiviral Therapy</i> , 2005, 10, 811-823. | 1.0 | 103 |
| 380 | Are Specific Antiretrovirals associated with an Increased Risk of Discontinuation due to Toxicities or Patient/Physician Choice in patients with Hepatitis C Virus Coinfection?. <i>Antiviral Therapy</i> , 2005, 10, 779-790. | 1.0 | 22 |
| 381 | Thymidine Analogue Mutation Profiles: Factors Associated with Acquiring Specific Profiles and their Impact on the Virological Response to Therapy. <i>Antiviral Therapy</i> , 2005, 10, 791-802. | 1.0 | 55 |
| 382 | Current Epidemiology of <i>Pneumocystis</i> Pneumonia. <i>Emerging Infectious Diseases</i> , 2004, 10, 1713-1720. | 4.3 | 387 |
| 383 | Predictors of Immunological Failure after Initial Response to Highly Active Antiretroviral Therapy in HIV-Infected Adults: A EuroSIDA Study. <i>Journal of Infectious Diseases</i> , 2004, 190, 148-155. | 4.0 | 58 |
| 384 | Starting highly active antiretroviral therapy: why, when and response to HAART. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 54, 10-13. | 3.0 | 28 |
| 385 | Commentary: Death in the era of potent antiretroviral therapy: shifting causes, new challenges. <i>International Journal of Epidemiology</i> , 2004, 34, 130-131. | 1.9 | 6 |
| 386 | Attenuation of the Bacterial Load in Blood by Pretreatment with Granulocyte-Colony-Stimulating Factor Protects Rats from Fatal Outcome and Brain Damage during <i>Streptococcus pneumoniae</i> Meningitis. <i>Infection and Immunity</i> , 2004, 72, 4647-4653. | 2.2 | 34 |
| 387 | Foscarnet used in salvage therapy of HIV-1 patients harbouring multiple nucleotide excision mutations. <i>Aids</i> , 2004, 18, 1076-1078. | 2.2 | 13 |
| 388 | Changing incidence of central nervous system diseases in the EuroSIDA cohort. <i>Annals of Neurology</i> , 2004, 55, 320-328. | 5.3 | 273 |
| 389 | The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003. <i>Cancer</i> , 2004, 100, 2644-2654. | 4.1 | 132 |
| 390 | Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome. <i>Scandinavian Journal of Infectious Diseases</i> , 2004, 36, 14-19. | 1.5 | 63 |
| 391 | Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. <i>Lancet, The</i> , 2004, 364, 51-62. | 13.7 | 303 |
| 392 | Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression. <i>Aids</i> , 2004, 18, 1795-1804. | 2.2 | 26 |
| 393 | Causes of death in HIV infection. <i>Aids</i> , 2004, 18, 2333-2337. | 2.2 | 34 |
| 394 | Clinical trial methodology and clinical cohorts: the importance of complete follow-up in trials evaluating the virological efficacy of anti-HIV medicines. <i>Current Opinion in Infectious Diseases</i> , 2004, 17, 33-37. | 3.1 | 4 |
| 395 | Dyslipidaemia and cardiovascular disease risk associated with antiretroviral drugs. <i>Pharmacoepidemiology and Drug Safety</i> , 2003, 12, 357-359. | 1.9 | 1 |
| 396 | Randomized Trial to Evaluate Indinavir/Ritonavir versus Saquinavir/Ritonavir in Human Immunodeficiency Virus Type 1-Infected Patients: The MaxCmin1 Trial. <i>Journal of Infectious Diseases</i> , 2003, 188, 635-642. | 4.0 | 118 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 397 | Anemia and Survival in Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2003, 37, S297-S303. | 5.8 | 46 |
| 398 | Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine. <i>Aids</i> , 2003, 17, 2045-2052. | 2.2 | 69 |
| 399 | Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. <i>Aids</i> , 2003, 17, 831-840. | 2.2 | 55 |
| 400 | Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study. <i>Aids</i> , 2003, 17, 1179-1193. | 2.2 | 770 |
| 401 | Combination Antiretroviral Therapy and the Risk of Myocardial Infarction. <i>New England Journal of Medicine</i> , 2003, 349, 1993-2003. | 27.0 | 1,560 |
| 402 | Virological rebound after suppression on highly active antiretroviral therapy. <i>Aids</i> , 2003, 17, 1741-1751. | 2.2 | 99 |
| 403 | Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study. <i>Aids</i> , 2003, 17, 1179-93. | 2.2 | 335 |
| 404 | Changes in Viral Load in People with Virological Failure who Remain on the Same Haart Regimen. <i>Antiviral Therapy</i> , 2003, 8, 127-136. | 1.0 | 24 |
| 405 | A Randomized Trial Comparing Initial Haart Regimens of Nelfinavir/Nevirapine and Ritonavir/Saquinavir in Combination with Two Nucleoside Reverse Transcriptase Inhibitors. <i>Antiviral Therapy</i> , 2003, 8, 595-602. | 1.0 | 6 |
| 406 | YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Purulent Meningitis. <i>Vaccine Journal</i> , 2002, 9, 598-604. | 3.1 | 58 |
| 407 | Association of Virus Load, CD4 Cell Count, and Treatment with Clinical Progression in Human Immunodeficiency Virus – Infected Patients with Very Low CD4 Cell Counts. <i>Journal of Infectious Diseases</i> , 2002, 186, 189-197. | 4.0 | 52 |
| 408 | A Clinically Prognostic Scoring System for Patients Receiving Highly Active Antiretroviral Therapy: Results from the EuroSIDA Study. <i>Journal of Infectious Diseases</i> , 2002, 185, 178-187. | 4.0 | 116 |
| 409 | Safe Interruption of Maintenance Therapy against Previous Infection with Four Common HIV-Associated Opportunistic Pathogens during Potent Antiretroviral Therapy. <i>Annals of Internal Medicine</i> , 2002, 137, 239. | 3.9 | 122 |
| 410 | Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. <i>Lancet, The</i> , 2002, 360, 119-129. | 13.7 | 1,415 |
| 411 | The Evaluation of Subcutaneous Proleukin® (interleukin-2) in a Randomized International Trial. <i>Contemporary Clinical Trials</i> , 2002, 23, 198-220. | 1.9 | 81 |
| 412 | Analysis of Virological Efficacy in Trials of Antiretroviral Regimens: Drawbacks of Not Including Viral Load Measurements after Premature Discontinuation of Therapy. <i>Antiviral Therapy</i> , 2002, 7, 271-281. | 1.0 | 14 |
| 413 | Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. <i>Aids</i> , 2001, 15, 2385-2395. | 2.2 | 61 |
| 414 | Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir. <i>Aids</i> , 2001, 15, 999-1008. | 2.2 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 415 | The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study. <i>Aids</i> , 2001, 15, 201-209. | 2.2 | 48 |
| 416 | Prognostic Markers of Short-term Mortality in AIDS-Associated <i>Pneumocystis carinii</i> Pneumonia. <i>Chest</i> , 2001, 119, 844-851. | 0.8 | 61 |
| 417 | Clinical correlation of variations in the internal transcribed spacer regions of rRNA genes in <i>Pneumocystis carinii</i> f.sp. <i>hominis</i> . <i>Aids</i> , 2001, 15, 451-459. | 2.2 | 48 |
| 418 | Highly active antiretroviral therapy and coronary heart disease: the need for perspective. <i>Aids</i> , 2001, 15, S193-S201. | 2.2 | 25 |
| 419 | Discontinuation of Secondary Prophylaxis against <i>Pneumocystis carinii</i> Pneumonia in Patients with HIV Infection Who Have a Response to Antiretroviral Therapy. <i>New England Journal of Medicine</i> , 2001, 344, 168-174. | 27.0 | 155 |
| 420 | Heterogeneity and Compartmentalization of <i>Pneumocystis carinii</i> f. sp. <i>hominis</i> Genotypes in Autopsy Lungs. <i>Journal of Clinical Microbiology</i> , 2001, 39, 3789-3792. | 3.9 | 30 |
| 421 | Influence of Age on CD4 Cell Recovery in Human Immunodeficiency Virus-Infected Patients Receiving Highly Active Antiretroviral Therapy: Evidence from the EuroSIDA Study. <i>Journal of Infectious Diseases</i> , 2001, 183, 1290-1294. | 4.0 | 219 |
| 422 | Inhibition of Leukocyte Entry into the Brain by the Selectin Blocker Fucoidin Decreases Interleukin-1 (IL-1) Levels but Increases IL-8 Levels in Cerebrospinal Fluid during Experimental Pneumococcal Meningitis in Rabbits. <i>Infection and Immunity</i> , 2000, 68, 3153-3157. | 2.2 | 58 |
| 423 | Virological Failure among Patients on Haart from across Europe: Results from the EuroSIDA Study. <i>Antiviral Therapy</i> , 2000, 5, 107-112. | 1.0 | 12 |
| 424 | Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. <i>Aids</i> , 1999, 13, 943-950. | 2.2 | 335 |
| 425 | Discontinuation of <i>Pneumocystis carinii</i> pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. <i>Lancet</i> , The, 1999, 353, 1293-1298. | 13.7 | 206 |
| 426 | Effects of mutations in <i>Pneumocystis carinii</i> dihydropteroate synthase gene on outcome of AIDS-associated <i>P. carinii</i> pneumonia. <i>Lancet</i> , The, 1999, 354, 1347-1351. | 13.7 | 254 |
| 427 | Regional survival differences across Europe In HIV-positive people: the EuroSIDA study. <i>Aids</i> , 1999, 13, 2281-2288. | 2.2 | 22 |
| 428 | Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy?. <i>Aids</i> , 1999, 13, 1647-1651. | 2.2 | 86 |
| 429 | Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. <i>Aids</i> , 1999, 13, 2075-2082. | 2.2 | 121 |
| 430 | A Comparison of Exposure Groups in the EuroSIDA Study: Starting Highly Active Antiretroviral Therapy (HAART), Response to HAART, and Survival. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 1999, 22, 369. | 2.1 | 45 |
| 431 | A Comparison of Exposure Groups in the EuroSIDA Study: Starting Highly Active Antiretroviral Therapy (HAART), Response to HAART, and Survival. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 1999, 22, 369. | 2.1 | 122 |
| 432 | Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial. <i>Aids</i> , 1999, 13, F9-F16. | 2.2 | 69 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 433 | Pretreatment with Granulocyte Colony-Stimulating Factor Attenuates the Inflammatory Response but Not the Bacterial Load in Cerebrospinal Fluid during Experimental Pneumococcal Meningitis in Rabbits. <i>Infection and Immunity</i> , 1999, 67, 3430-3436. | 2.2 | 20 |
| 434 | XVI. The <i>Pneumocystis carinii</i> major surface glycoprotein (MSG): its potential involvement in the pathophysiology of pneumocystosis. <i>FEMS Immunology and Medical Microbiology</i> , 1998, 22, 129-134. | 2.7 | 9 |
| 435 | Changes in use of antiretroviral therapy in regions of Europe over time. <i>Aids</i> , 1998, 12, 2031-2039. | 2.2 | 51 |
| 436 | Survival in 2367 Zidovudine-Treated Patients According to Use of Other Nucleoside Analogue Drugs. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1998, 17, 239-244. | 0.3 | 16 |
| 437 | XVI. The <i>Pneumocystis carinii</i> major surface glycoprotein (MSG): its potential involvement in the pathophysiology of pneumocystosis. <i>FEMS Immunology and Medical Microbiology</i> , 1998, 22, 129-134. | 2.7 | 2 |
| 438 | Update on <i>Pneumocystis carinii</i> f. sp. <i>hominis</i> Typing Based on Nucleotide Sequence Variations in Internal Transcribed Spacer Regions of rRNA Genes. <i>Journal of Clinical Microbiology</i> , 1998, 36, 734-741. | 3.9 | 133 |
| 439 | Diagnostic Use of PCR for Detection of <i>Pneumocystis carinii</i> in Oral Wash Samples. <i>Journal of Clinical Microbiology</i> , 1998, 36, 2068-2072. | 3.9 | 103 |
| 440 | Human Herpes Virus-8 DNA in Bronchoalveolar Lavage Samples from Patients with AIDS-associated Pulmonary Kaposi's Sarcoma. <i>Scandinavian Journal of Infectious Diseases</i> , 1997, 29, 13-16. | 1.5 | 35 |
| 441 | Toxoplasmosis in Danish AIDS Patients. <i>Scandinavian Journal of Infectious Diseases</i> , 1997, 29, 597-600. | 1.5 | 15 |
| 442 | Rapid Detection of Cytomegalovirus in Bronchoalveolar Lavage Fluid and Serum Samples by Polymerase Chain Reaction: Correlation of Virus Isolation and Clinical Outcome for Patients with Human Immunodeficiency Virus Infection. <i>Clinical Infectious Diseases</i> , 1997, 24, 878-883. | 5.8 | 7 |
| 443 | Neutrophil Chemotactic Activity in Bronchoalveolar Lavage Fluid of Patients with AIDS-associated <i>Pneumocystis carinii</i> Pneumonia. <i>Scandinavian Journal of Infectious Diseases</i> , 1997, 29, 367-371. | 1.5 | 18 |
| 444 | Regional Differences in Use of Antiretroviral Agents and Primary Prophylaxis in 3122 European HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1997, 16, 153-160. | 0.3 | 58 |
| 445 | Factors associated with the CD4+ lymphocyte count at diagnosis of acquired immunodeficiency syndrome. <i>Journal of Clinical Epidemiology</i> , 1996, 49, 1253-1258. | 5.0 | 12 |
| 446 | Newer Therapies for <i>Pneumocystis carinii</i> Pneumonia. <i>Clinical Pulmonary Medicine</i> , 1996, 3, 304-313. | 0.3 | 4 |
| 447 | Epidemiology of AIDS-related Kaposi's sarcoma in Europe over 10 years. <i>Aids</i> , 1996, 10, 911-918. | 2.2 | 48 |
| 448 | Evaluation of PCR technique for Diagnosing <i>Pneumocystis carinii</i> Pneumonia in HIV Positive Patients using Oropharyngeal washings. <i>Journal of Eukaryotic Microbiology</i> , 1996, 43, 9S-9S. | 1.7 | 9 |
| 449 | Antibody Responses to <i>Pneumocystis carinii</i> in Hospital Personal with and without Exposure to Patients with <i>P. carinii</i> Pneumonia. <i>Journal of Eukaryotic Microbiology</i> , 1996, 43, 10S-10S. | 1.7 | 5 |
| 450 | Prognostic Value of Interleukin-8 in AIDS-associated <i>Pneumocystis carinii</i> Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1995, 151, 1058-1062. | 5.6 | 25 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 451 | Changing Patterns of Kaposi's Sarcoma in Danish Acquired Immunodeficiency Syndrome Patients with Complete Follow-up. <i>American Journal of Epidemiology</i> , 1995, 141, 652-658. | 3.4 | 35 |
| 452 | Changes in Survival Over Time After a First Episode of <i>Pneumocystis carinii</i> Pneumonia for European Patients With Acquired Immunodeficiency Syndrome. <i>Archives of Internal Medicine</i> , 1995, 155, 822. | 3.8 | 16 |
| 453 | Does Cytomegalovirus Predict a Poor Prognosis in <i>Pneumocystis carinii</i> Pneumonia Treated With Corticosteroids?. <i>Chest</i> , 1995, 108, 411-414. | 0.8 | 48 |
| 454 | Does the onset of tuberculosis in AIDS predict shorter survival? Results of a cohort study in 17 European countries over 13 years. <i>BMJ: British Medical Journal</i> , 1995, 311, 1468-1471. | 2.3 | 49 |
| 455 | PAF receptor antagonists in the treatment of asthma. <i>Expert Opinion on Investigational Drugs</i> , 1994, 3, 733-742. | 4.1 | 4 |
| 456 | The Efficacy of Zidovudine Is Time Limited-Reply. <i>JAMA - Journal of the American Medical Association</i> , 1994, 272, 1001. | 7.4 | 0 |
| 457 | A sex comparison of rates of new AIDS-defining disease and death in 2554 AIDS cases. <i>Aids</i> , 1994, 8, 831-836. | 2.2 | 58 |
| 458 | Effects of inhibitors of arachidonic acid metabolism on serotonin release from rat basophilic leukemia cells. <i>Immunopharmacology</i> , 1993, 25, 131-144. | 2.0 | 14 |
| 459 | IgM Response to a Human <i>Pneumocystis carinii</i> Surface Antigen in HIV-infected Patients with Pulmonary Symptoms. <i>Scandinavian Journal of Infectious Diseases</i> , 1993, 25, 515-520. | 1.5 | 17 |
| 460 | Serum Type III Procollagen Peptide in Patients with <i>Pneumocystis carinii</i> Infection. <i>The American Review of Respiratory Disease</i> , 1993, 148, 1558-1562. | 2.9 | 17 |
| 461 | Amount of <i>Pneumocystis carinii</i> and Degree of Acute Lung Inflammation in HIV-associated <i>P. carinii</i> Pneumonia. <i>Chest</i> , 1993, 104, 109-113. | 0.8 | 25 |
| 462 | Antibody Responses to a Major <i>Pneumocystis carinii</i> Antigen in Human Immunodeficiency Virus-Infected Patients with and without <i>P. carinii</i> Pneumonia. <i>Journal of Infectious Diseases</i> , 1992, 165, 1151-1155. | 4.0 | 47 |
| 463 | HIV-associated lymphoma: Histopathology and association with Epstein-Barr virus genome related to clinical, immunological and prognostic features. <i>European Journal of Cancer & Clinical Oncology</i> , 1991, 27, 1416-1423. | 0.7 | 73 |
| 464 | Substance P and Neurokinin A in Human Nasal Mucosa. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1991, 4, 228-236. | 2.9 | 157 |
| 465 | Platelet-Activating Factor Stimulates Eicosanoid Production in Cultured Feline Tracheal Explants. <i>Experimental Lung Research</i> , 1991, 17, 1079-1094. | 1.2 | 10 |
| 466 | Pathogenesis of airway mucus hypersecretion. <i>Journal of Allergy and Clinical Immunology</i> , 1990, 85, 399-417. | 2.9 | 123 |
| 467 | Substance P Receptor-Mediated Secretion of Respiratory Glycoconjugate from Feline Airways in Vitro. <i>Experimental Lung Research</i> , 1989, 15, 17-29. | 1.2 | 41 |
| 468 | The whole-mount method as a technique for measuring experimental changes in airway goblet cell number. <i>Apmis</i> , 1989, 97, 1141-1145. | 2.0 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 469 | Dexamethasone Reduces Rat Tracheal Goblet Cell Hyperplasia Produced by Human Neutrophil Products. <i>Experimental Lung Research</i> , 1988, 14, 853-863. | 1.2 | 44 |
| 470 | Dexamethasone Inhibits Respiratory Glycoconjugate Secretion from Feline Airways In Vitro by the Induction of Lipocortin (Lipomodulin) Synthesis. <i>The American Review of Respiratory Disease</i> , 1988, 137, 353-357. | 2.9 | 68 |
| 471 | The Effects of Endorphins on Mucous Glycoprotein Secretion from Feline Airways in Vitro. <i>Experimental Lung Research</i> , 1987, 12, 303-309. | 1.2 | 10 |